[en] Objectives To compare the outcomes of sickle cell disease patients diagnosed through neonatal screening with those who were not. Methods In an observational multicenter study in Belgium, 167 screened and 93 unscreened sickle cell disease patients were analyzed for a total of 1116 and 958 patient-years of follow-up, respectively. Both groups were compared with propensity score analysis, with patients matched on three covariates (gender, genotype, and central Africa origin). Bonferroni correction was applied for all comparisons. Results Kaplan-Meier estimates of survival without bacteremia were significantly higher in the screened group than the unscreened group (94.47%; [95% CI, 88.64-97.36%] versus 83.78% [95% CI, 72.27-90.42%]), p = 0.032. Non-significant differences between both groups were reported for survival without acute chest syndrome, acute anemia, cerebral complication, severe infection, and vaso-occlusive crisis. Significantly lower hospitalization rate and days per 100 patient-years were observed in the screened compared with the unscreened group (0.27 vs. 0.63 and 1.25 vs. 2.82, p = 0.0006 and <0.0001). Conclusion These data confirm the benefit of a neonatal screening programme in reducing bacteremia and hospitalization.
Disciplines :
Pédiatrie Hématologie
Auteur, co-auteur :
Lê, Phu-Quoc
Ferster, A
Dedeken, L
Vermylen, C
Vanderfaeillie, A
Rozen, L
Heijmans, C
Huybrechts, S
Devalck, C
Cotton, F
Ketelslegers, O
Dresse, Marie-Françoise ; Centre Hospitalier Universitaire de Liège - CHU > Department of Pediatrics,University Hospital Liège > CHR Citadelle, Liège, Belgium
Weatherall DJ. The inherited diseases of hemoglobin are an emerging global health burden. Blood 2010; 115: 4331-4336.
Piel FB, Patil AP, Howes RE, et al. Global epidemiology of sickle haemoglobin in neonates: A contemporary geostatistical model-based map and population estimates. Lancet 2013; 381: 142-151.
Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia. N Engl J Med 1986; 314: 1593-1599.
Serjeant GR and Serjeant BE. Management of sickle cell disease: Lessons from the Jamaican Cohort Study. Blood Rev 1993; 7: 137-145.
Gill FM, Sleeper LA, Weiner SJ, et al. Clinical events in the first decade in a cohort of infants with sickle cell disease. Cooperative Study of Sickle Cell Disease [see comments]. Blood 1995; 86: 776-783.
Lê PQ, Ferster A, Cotton F, et al. Sickle cell disease from Africa to Belgium, from neonatal screening to clinical management. Me´decine Trop Rev Corps Sante´ Colon 2010; 70: 467-470.
Lê PQ, Gulbis B, Dedeken L, et al. Survival among children and adults with sickle cell disease in Belgium: Benefit from hydroxyurea treatment. Pediatr Blood Cancer 2015; 62: 1956-1961.
Gulbis B, Ferster A, Vermylen C, et al. An estimation of the incidence and demographic picture of the major hemoglobinopathies in Belgium (from a confidential inquiry). Hemoglobin 2008; 32: 279-285.
Boemer F, Cornet Y, Libioulle C, et al. 3-years experience review of neonatal screening for hemoglobin disorders using tandem mass spectrometry. Clin Chim Acta 2011; 412: 1476-1479.
Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 1995; 332: 1317-1322.
Ferster A, Vermylen C, Cornu G, et al. Hydroxyurea for treatment of severe sickle cell anemia: A pediatric clinical trial. Blood 1996; 88: 1960-1964.
Thornburg CD, Files BA, Luo Z, et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood 2012; 120: 4304-4310.
Vermylen C, Cornu G, Ferster A, et al. Haematopoietic stem cell transplantation for sickle cell anaemia: The first 50 patients transplanted in Belgium. Bone Marrow Transplant 1998; 22: 1-6.
Bernaudin F, Socie G, Kuentz M, et al. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood 2007; 110: 2749-2756.
Panepinto JA, Walters MC, Carreras J, et al. Matched-related donor transplantation for sickle cell disease: Report from the Center for International Blood and Transplant Research. Br J Haematol 2007; 137: 479-485.
Dedeken L, Lê PQ, Azzi N, et al. Haematopoietic stem cell transplantation for severe sickle cell disease in childhood: A single centre experience of 50 patients. Br J Haematol 2014; 165: 402-408.
de Montalembert M, Brousse V, Elie C, et al. Long-term hydroxyurea treatment in children with sickle cell disease: Tolerance and clinical outcomes. Haematologica 2006; 91: 125-128.
de Montalembert M, Ferster A, Colombatti R, et al. ENERCA clinical recommendations for disease management and prevention of complications of sickle cell disease in children. Am J Hematol 2011; 86: 72-75.
Ware RE. How I use hydroxyurea to treat young patients with sickle cell anemia. Blood 2010; 115: 5300-5311.
Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: Summary of the 2014 evidence-based report by expert panel members. JAMA 2014; 312: 1033-1048.
Imai K and Ratkovic M. Robust estimation of inverse probability weights for marginal structural models. J Am Stat Assoc 2014; 110: 1013-1023.
Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011; 46: 399-424.
Austin PC. The performance of different propensity-score methods for estimating marginal hazard ratios. Stat Med 2013; 32: 2837-2849.
Xie J and Liu C. Adjusted Kaplan-Meier estimator and log-rank test with inverse probability of treatment using weighting for survival data. Stat Med 2005; 24: 3089-3110.
Vichinsky E, Hurst D, Earles A, et al. Newborn screening for sickle cell disease: Effect on mortality. Pediatrics 1988; 81: 749-755.
Telfer P, Coen P, Chakravorty S, et al. Clinical outcomes in children with sickle cell disease living in England: A neonatal cohort in East London. Haematologica 2007; 92: 905-912.
Quinn CT, Rogers ZR and Buchanan GR. Survival of children with sickle cell disease. Blood 2004; 103: 4023-4027.
Quinn CT, Rogers ZR, McCavit TL, et al. Improved survival of children and adolescents with sickle cell disease. Blood 2010; 115: 3447-3452.
Sabarense AP, Lima GO, Silva LML, et al. Characterization of mortality in children with sickle cell disease diagnosed through the Newborn Screening Program. J Pediatr (Rio J) 2015; 91: 242-247.
Goldblatt D, Johnson M and Evans J. Antibody responses to Haemophilus influenzae type b conjugate vaccine in sickle cell disease. Arch Dis Child 1996; 75: 159-161.
Adamkiewicz TV, Silk BJ, Howgate J, et al. Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life. Pediatrics 2008; 121: 562-569.
Couque N, Girard D, Ducrocq R, et al. Improvement of medical care in a cohort of newborns with sickle-cell disease in North Paris: Impact of national guidelines. Br J Haematol 2016; 173: 927-937.
Ketelslegers O, Eyskens F, Boemer F, et al. Epidemiological data on sickle cell disease in Belgium. Belg J Hematol 2015; 6.
